Marriage Of Kite’s CAR-T Platform To Amgen Targets Will Expand Pipeline For Both
This article was originally published in The Pink Sheet Daily
Kite’s initial partnership with another biopharma sees it bringing its CAR-T platform technology to bear on Amgen’s oncology targets. Each company could develop new cancer immunotherapy products out of the collaboration, with earn-outs for the other.
You may also be interested in...
FDA approves Biogen’s long-acting hemophilia drug Alprolix and lifts clinical hold on Curis’ cancer drug CUDC-427, but Amgen’s announcement that its melanoma vaccine T-VEC failed to improve survival clouds its chances with the agency.
France plans to begin issuing manufacturing quality certificates so firms can import ordinary cosmetics into China without animal testing under a 2020 draft regulation. The Personal Care Products Council is working to find a comparable solution for US manufacturers.
The calcineurin inhibitor, only the second drug to be approved by the US FDA for lupus nephritis, will be competing against GlaxoSmithKline’s Benlysta.